Cereno Scientific strengthens its pipeline for the second time this year

10 December, 2019

Cereno Scientific is developing a platform of cardiovascular therapies in the new field of epigenetics based on HDAC inhibition. Having previously concentrated solely on the prevention of thrombosis, 2019 has brought on a widened scope that also includes rare diseases with indications associated with fibrosis, inflammation and high blood pressure in the lung. Today, a new asset was acquired to the company’s R&D platform.

Read the full article on BioStock here.